Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer
Authors
Keywords
-
Journal
BMC CANCER
Volume 11, Issue 1, Pages -
Publisher
Springer Nature
Online
2011-07-06
DOI
10.1186/1471-2407-11-286
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- High Expression of HIF1a Is a Predictor of Clinical Outcome in Patients with Pancreatic Ductal Adenocarcinomas and Correlated to PDGFA, VEGF, and bFGF
- (2015) Andreas-Claudius Hoffmann et al. NEOPLASIA
- Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer
- (2010) Kyung A Kwon et al. BMC CANCER
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
- (2010) Hedy Lee Kindler et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205
- (2010) Philip A. Philip et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Bevacizumab With Concurrent Capecitabine and Radiation Followed by Maintenance Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer: Radiation Therapy Oncology Group RTOG 0411
- (2009) Christopher H. Crane et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
- (2009) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Angiopoietin 2 Is a Partial Agonist/Antagonist of Tie2 Signaling in the Endothelium
- (2009) H. T. Yuan et al. MOLECULAR AND CELLULAR BIOLOGY
- Biomarkers of response and resistance to antiangiogenic therapy
- (2009) Rakesh K. Jain et al. Nature Reviews Clinical Oncology
- Pancreatic cancer: molecular pathogenesis and new therapeutic targets
- (2009) Han H. Wong et al. Nature Reviews Gastroenterology & Hepatology
- Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system
- (2009) Hellmut G. Augustin et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Serum Vascular Endothelial Growth Factor/Soluble Vascular Endothelial Growth Factor Receptor 1 Ratio Is an Independent Prognostic Marker in Pancreatic Cancer
- (2009) Yu-Ting Chang et al. PANCREAS
- Most Pancreatic Cancer Resections are R1 Resections
- (2008) Irene Esposito et al. ANNALS OF SURGICAL ONCOLOGY
- Role of platelet-derived growth factors in physiology and medicine
- (2008) J. Andrae et al. GENES & DEVELOPMENT
- A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
- (2008) Andrew H. Ko et al. INVESTIGATIONAL NEW DRUGS
- Tumor Angiogenesis
- (2008) Robert S. Kerbel NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now